Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies - Nadal, R; Mortazavi, A; Stein, M (2017)
Paper presented at: European Society of Medical Oncology (ESMO)